<DOC>
	<DOCNO>NCT01214616</DOCNO>
	<brief_summary>- To identify Maximum Tolerated Dose ( MTD ) afatinib combination vinorelbine i.v . assessment Dose Limiting Toxicities ( DLT ) ; - To assess safety anti-tumour efficacy determine pharmacokinetic characteristic afatinib vinorelbine i.v .</brief_summary>
	<brief_title>BIBW 2992 ( Afatinib ) Vinorelbine Japanese Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm diagnosis malignancy advance standard therapy exist longer effective . Life expectancy least 12 week Eastern Cooperative Oncology Group Performance Status 0 1 Adequate hepatic , renal , haematologic organ function Written inform consent Exclusion criterion : Chemotherapy , immunotherapy , surgery radiotherapy within past 4 week Prior treatment afatinib vinorelbine Clinically significant active infectious disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>